Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Cellectis gains on first human data for UCART19

    Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) gained $6.27 (18%) to $41.28 on NASDAQ and EUR 3.60 to EUR 36.10 on Euronext on Thursday after U.K. researchers reported that the biotech's UCART19 produced remission in a …

    Published on 11/5/2015
  • CLINICAL NEWS: FDA reviewers accept sugammadex data

    In briefing documents posted ahead of an FDA advisory committee meeting to review a resubmitted NDA for sugammadex from Merck & Co. Inc. (NYSE:MRK), agency reviewers said the company has resolved the agency's concerns …

    Published on 11/4/2015
  • CLINICAL NEWS: Alnylam, SOM Biotech, Isis update TTR programs

    Data presented at the European Congress on Hereditary ATTR amyloidosis included results from clinical studies of transthyretin amyloid disease therapies from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), SOM Biotech S.L.…

    Published on 11/3/2015
  • CLINICAL NEWS: Aquinox slips after Phase II dermatitis miss

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) lost $0.94 to $15.42 on Tuesday after its AQX-1125 missed the primary endpoint in the Phase II KINSHIP trial to treat atopic dermatitis. The company said the results "do not …

    Published on 11/3/2015
  • CLINICAL NEWS: Revance rises on Phase II data for Botox competitor

    Revance Therapeutics Inc. (NASDAQ:RVNC) jumped $10.86 (41%) to $37.59 on Thursday after an interim analysis showed RT002 met the primary endpoints in the Phase II BELMONT study to treat glabellar lines. The therapy had …

    Published on 10/29/2015
  • CLINICAL NEWS: AZ's olaparib leads to responses in CRPC

    Data published Wednesday in the New England Journal of Medicine showed olaparib (AZD2281) from AstraZeneca plc (LSE:AZN; NYSE:AZN) led to a response in 33% of patients in the Phase II TOPARP-A study to treat castration-…

    Published on 10/28/2015
  • CLINICAL NEWS: Intercept reports NASH data from Japanese study

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) slipped $3.51 to $164.13 on Wednesday after reporting data from a Phase II trial of obeticholic acid (OCA; DSP-1747) in Japanese non-alcoholic steatohepatitis (NASH) patients…

    Published on 10/28/2015
  • CLINICAL NEWS: Agios rises in advance of AG-120 presentation

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO) gained $16.09 (25%) to $80.94 on Tuesday after it said it would present results from a Phase I study of AG-120 in patients with isocitrate dehydrogenase 1 (IDH1)-mutant positive …

    Published on 10/27/2015
  • CLINICAL NEWS: GSK's losmapimod fails ACS efficacy analysis

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said losmapimod (GW856553) failed to show efficacy against the primary endpoint in an interim analysis of the Phase III LATITUDE-TIMI 60 study to treat acute coronary syndrome (…

    Published on 10/27/2015
  • CLINICAL NEWS: Shire to resubmit lifitegrast NDA with OPUS-3 data

    Shire plc (LSE:SHP; NASDAQ:SHPG) said lifitegrast (SHP606) met the primary endpoint in the Phase III OPUS-3 trial to treat dry eye, putting the candidate on track for a 1Q16 NDA resubmission and potential 2016 U.S. …

    Published on 10/27/2015
  • CLINICAL NEWS: Merck's Keytruda improves OS in NSCLC study

    Merck & Co. Inc. (NYSE:MRK) said top-line data showed Keytruda pembrolizumab significantly increased overall survival compared with docetaxel in the Phase II/III KEYNOTE-010 trial to treat metastatic non-small cell lung…

    Published on 10/26/2015
  • CLINICAL NEWS: Zafgen closes beloranib trials

    Zafgen Inc. (NASDAQ:ZFGN) said it will close the randomized portions of its Phase III bestPWS (ZAF-311) and Phase IIb ZAF-203 trials of obesity candidate beloranib (ZGN-440). The company said that it will analyze data …

    Published on 10/22/2015
  • CLINICAL NEWS: Synta halting ganetespib study after futility analysis

    Synta Pharmaceuticals Corp. (NASDAQ:SNTA) sank $1.30 (64%) to $0.74 after it said it will terminate the Phase III GALAXY-2 trial of ganetespib (STA-9090) to treat advanced non-small cell lung cancer (NSCLC). Synta said …

    Published on 10/21/2015
  • CLINICAL NEWS: Eight-week data for Merck's triple HCV combo

    An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-…

    Published on 10/20/2015
  • CLINICAL NEWS: Shorter ABT-493/ABT-530 regimen yields 100% SVR4

    An abstract released ahead of the American Association for the Study of Liver Diseases (AASLD) meeting showed an eight-week regimen of ABT-493 from AbbVie Inc. (NYSE:ABBV) and Enanta Pharmaceuticals Inc. (NASDASQ:ENTA) …

    Published on 10/20/2015
  • CLINICAL NEWS: Genocea sinks on Phase IIa miss

    Genocea Biosciences Inc. (NASDAQ:GNCA) slumped $2.06 (28%) to $5.17 on Monday after GEN-004 missed the primary endpoints in a Phase IIa study to vaccinate against Streptococcus pneumoniae.In the 98-patient trial, the …

    Published on 10/19/2015
  • CLINICAL NEWS: J&J's Stelara meets Phase III Crohn's endpoint

    The Janssen unit of Johnson & Johnson (NYSE:JNJ) said Stelara ustekinumab met the primary endpoint in the Phase III UNITI-2 study to treat moderate to severe Crohn's disease. Spokesperson Brian Kenney said Janssen is …

    Published on 10/19/2015
  • CLINICAL NEWS: Cempra meets Phase III endpoint, sinks on safety concerns

    Cempra Inc. (NASDAQ:CEMP) fell $7.49 (28%) to $19.29 on Friday after reporting data from the Phase III Solitaire-IV study of IV solithromycin (CEM-101) to treat community-acquired bacterial pneumonia (CABP). Cempra said…

    Published on 10/16/2015
  • CLINICAL NEWS: PTC's Translarna submission ongoing despite Phase III miss

    PTC Therapeutics Inc. (NASDAQ:PTCT) gained $3.26 (10%) to $33 in after-hours trading Thursday after it reported data from the Phase III ACT DMD study of Translarna ataluren to treat nonsense mutation Duchenne muscular …

    Published on 10/15/2015
  • CLINICAL NEWS: Baricitinib tops Humira in Phase III RA study

    Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said baricitinib (LY3009104) met the primary outcome of superiority to placebo and also was superior to Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in the …

    Published on 10/14/2015
  • CLINICAL NEWS: CurePSP program recruits patients for AbbVie, BMS trials

    Non-profit CurePSP (Timonium, Md.) said it formed the Patient Engagement Program to assist in patient recruitment for clinical trials to treat degenerative brain diseases including progressive supranuclear palsy (PSP).…

    Published on 10/14/2015
  • CLINICAL NEWS: Ultragenyx reports interim LC-FAOD data

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell $7.40 to $82.49 on Tuesday after releasing interim results from a Phase IIb study of triheptanoin (UX007) to treat long-chain fatty acid oxidation disorders. The company…

    Published on 10/13/2015
  • CLINICAL NEWS: AZ suspends two NSCLC combo trials

    AstraZeneca plc (LSE:AZN; NYSE:AZN) temporarily suspended the Phase Ib TATTON trial and Phase III CAURAL trial of AZD9291 in combination with durvalumab (MEDI4736) to treat non-small cell lung cancer (NSCLC). …

    Published on 10/9/2015
  • CLINICAL NEWS: BioCryst sinks on HAE updates

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) lost $2.12 (18%) to $9.75 on Thursday after slowing its development timeline for hereditary angioedema therapy avoralstat (BCX4161) and disclosing discussions with FDA that …

    Published on 10/8/2015
  • CLINICAL NEWS: Neurocrine gains on Phase III dyskinesia data

    Neurocrine Biosciences Inc. (NASDAQ:NBIX) gained $4.67 (12%) to $43.60 after its NBI-98854 met the primary endpoint in the Phase III Kinect 3 trial to treat tardive dyskinesia. Daily 80 mg doses of NBI-98854 …

    Published on 10/8/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993